Χώρα: Καναδάς
Γλώσσα: Αγγλικά
Πηγή: Health Canada
LEFLUNOMIDE
PHARMASCIENCE INC
L04AA13
LEFLUNOMIDE
10MG
TABLET
LEFLUNOMIDE 10MG
ORAL
30/100
Prescription
DISEASE-MODIFYING ANTIRHEUMATIC AGENTS
Active ingredient group (AIG) number: 0140182001; AHFS:
APPROVED
2006-11-10
PRODUCT MONOGRAPH PR PMS-LEFLUNOMIDE Leflunomide Tablets, House Standard 10 mg and 20 mg Antirheumatic, Immunomodulator Agent PHARMASCIENCE INC. 6111 Royalmount Avenue, Suite 100 Montréal, Québec H4P 2T4 www.pharmascience.com Date of Revision: January 27, 2016 Submission Control No.: 190194 _pms-LEFLUNOMIDE Product Monograph _ _Page 2 of 69_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ...............................................................3 INDICATIONS AND CLINICAL USE .....................................................................3 CONTRAINDICATIONS ..........................................................................................3 WARNINGS AND PRECAUTIONS .........................................................................5 ADVERSE REACTIONS .........................................................................................14 DRUG INTERACTIONS .........................................................................................19 DOSAGE AND ADMINISTRATION .....................................................................23 OVERDOSAGE .......................................................................................................24 ACTION AND CLINICAL PHARMACOLOGY ...................................................25 STORAGE AND STABILITY .................................................................................27 DOSAGE FORMS, COMPOSITION AND PACKAGING ....................................28 PART II: SCIENTIFIC INFORMATION ................................................................................29 PHARMACEUTICAL INFORMATION .................................................................29 CLINICAL TRIALS .................................................................................................30 DETAILED PHARMACOLOGY ............................................................................38 TOXICOLOGY .................................... Διαβάστε το πλήρες έγγραφο